Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medical Nutrition Equity Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Medical Nutrition Equity Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2018 · fourth_quarter · Q4
HR 5340/S1390: Stronger Patents Act
-Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Newborn Screening
Source: Senate LDA
Medicare IVIG Access Enhancement Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
Medicare IVIG Access Enhancement Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
STRONGER Patents Act of 2018
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 5340/S1390: Stronger Patents Act
STRONGER Patents Act of 2018
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 5340/S1390: Stronger Patents Act
SUPPORT for Patients and Communities Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
SUPPORT for Patients and Communities Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Medical Nutrition Equity Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Medical Nutrition Equity Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
STRONGER Patents Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 5340/S1390: Stronger Patents Act
STRONGER Patents Act of 2017
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
HR 5340/S1390: Stronger Patents Act
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
Orphan drug tax credit
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Committee on Foreign Investment in the United States (CFIUS) reform
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2018 · third_quarter · Q3
HR 5340/S1390: Stronger Patents Act
Orphan drug tax credit
-Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Newborn Screening
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
Committee on Foreign Investment in the United States (CFIUS) reform
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE